Oncotype DCIS – pro
Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer that comprises up to 25 % of mammographically detected breast cancers [15]. The goals of treatment are to minimize the risk of local recurrence (LR) and invasive breast cancer while maximizing breast preservation. To that end, individualization of therapy would depend on a marker. Oncotype DCIS purports to help do that, by providing an assessment of risk, but it has not been tested in a prospective fashion and not included in NCCN or other guidelines.
Swati Kulkarni Management of DCISA Work in Progress ONCOLOGY. Vol. 25 No. 9, 2011
E. Rakowski et al, A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Research and Treatment July 2015, Volume 152, Issue 2, pp 389398